Editas Medicine, Inc. (EDIT)
2.40
-0.09
(-3.61%)
USD |
NASDAQ |
Oct 23, 16:00
2.385
-0.02
(-0.62%)
After-Hours: 20:00
Editas Medicine Price : 2.40 for Oct. 23, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | 2.44 | 2.45 | 2.30 | 2.40 | 1.314M |
| Oct 22, 2026 | 2.47 | 2.58 | 2.45 | 2.49 | 1.066M |
| Oct 21, 2026 | 2.59 | 2.60 | 2.50 | 2.51 | 1.139M |
| Oct 20, 2026 | 2.40 | 2.665 | 2.35 | 2.58 | 2.266M |
| Oct 19, 2026 | 2.38 | 2.43 | 2.27 | 2.42 | 2.011M |
| Oct 16, 2026 | 2.44 | 2.47 | 2.33 | 2.35 | 1.552M |
| Oct 15, 2026 | 2.26 | 2.465 | 2.25 | 2.44 | 1.860M |
| Oct 14, 2026 | 2.44 | 2.475 | 2.245 | 2.27 | 2.829M |
| Oct 13, 2026 | 2.73 | 2.73 | 2.44 | 2.445 | 2.454M |
| Oct 12, 2026 | 2.90 | 2.91 | 2.73 | 2.75 | 1.297M |
| Oct 09, 2026 | 2.85 | 2.97 | 2.71 | 2.90 | 3.088M |
| Oct 08, 2026 | 2.79 | 2.945 | 2.69 | 2.84 | 6.068M |
| Oct 07, 2026 | 2.71 | 2.845 | 2.659 | 2.75 | 2.265M |
| Oct 06, 2026 | 2.85 | 2.895 | 2.715 | 2.73 | 2.969M |
| Oct 05, 2026 | 2.62 | 2.81 | 2.555 | 2.79 | 3.019M |
| Oct 02, 2026 | 2.57 | 2.63 | 2.51 | 2.62 | 2.163M |
| Oct 01, 2026 | 2.61 | 2.62 | 2.52 | 2.52 | 1.544M |
| Sep 30, 2026 | 2.61 | 2.72 | 2.55 | 2.57 | 1.626M |
| Sep 29, 2026 | 2.54 | 2.62 | 2.51 | 2.59 | 1.570M |
| Sep 28, 2026 | 2.55 | 2.55 | 2.42 | 2.51 | 2.204M |
| Sep 25, 2026 | 2.76 | 2.78 | 2.57 | 2.58 | 3.119M |
| Sep 24, 2026 | 2.66 | 2.76 | 2.545 | 2.75 | 2.590M |
| Sep 23, 2026 | 3.12 | 3.14 | 2.67 | 2.69 | 5.167M |
| Sep 22, 2026 | 2.86 | 2.93 | 2.805 | 2.92 | 2.296M |
| Sep 21, 2026 | 2.76 | 2.89 | 2.695 | 2.83 | 2.491M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Recursion Pharmaceuticals, Inc. | 3.70 |
| Alnylam Pharmaceuticals, Inc. | 224.03 |
| Geron Corp. | 1.12 |
| Halozyme Therapeutics, Inc. | 125.63 |
| Novavax, Inc. | 9.70 |
Price Related Metrics
| PS Ratio | 5.164 |
| Price to Book Value | 3.500 |
| Earnings Yield | -31.02% |
| Market Cap | 368.47M |